Testosterone then enzalutamide to stop prostate cancer spread
Treatments studied
Part of Cancer, Hormones & metabolism clinical trials.
This Phase 2 trial tests whether giving testosterone first, then enzalutamide (a prostate cancer hormone-blocking pill), can slow or prevent worsening metastatic prostate cancer. It is designed for men whose cancer progressed despite ongoing hormone-suppression treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 or older and have confirmed prostate adenocarcinoma (prostate cancer type).
- Your cancer has spread to other parts of the body on CT scan or bone scan.
- You have been on continuous hormone suppression (like surgery or monthly/periodic injections) and your testosterone is at castrate level (<50 ng/dL).
- Your prostate cancer progressed while on abiraterone plus hormone therapy, based on PSA rise and/or scan changes.
- You have not taken enzalutamide (or similar prostate hormone drugs like apalutamide or darolutamide) before.
- You can do study requirements: enough blood counts and organ function, no serious uncontrolled infections, and you can sign consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests whether abiraterone, enzalutamide, or apalutamide can work better (or differently) in men with prostate cancer that is considered “castration-sensitive.” It compares these hormone-blocking treatments to find an approach that controls the cancer more effectively and safely.
This Phase 2 study tests whether adding ZEN003694 to enzalutamide works better than enzalutamide alone in men whose prostate cancer has spread and is no longer controlled by hormone lowering treatments. It focuses on people who either did not respond well to abiraterone (poor responders) or did respond (responders), then compares outcomes between treatment groups.
This trial tests a new radioactive drug (177Lu-TLX591) plus standard care against standard care alone for men with metastatic castration-resistant prostate cancer that has progressed on an androgen receptor pathway inhibitor. The goal is to see if this targeted radiation can help control the cancer.
This Phase 1 trial tests a new medicine (TVB-2640) combined with enzalutamide in men with prostate cancer that has spread and is no longer responding to hormone treatment. It aims to find a safe dose and see how well the treatment can work against the cancer.
This trial tests a combination of high-dose testosterone with enzalutamide and difluoromethylornithine (DFMO) for men whose prostate cancer has spread and stopped responding to standard hormone therapy. It aims to see if this approach can shrink tumors or slow the cancer's growth.
This trial tests whether adding a drug called enzalutamide to standard radiation and metastasis-directed therapy improves outcomes for men with recurrent prostate cancer that has spread to a few spots. It's for those whose PSA is rising quickly.
Hear when a new Castration Resistant Metastatic Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.